33 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
3
Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.

Sichuan University
20
Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).

Amgen
19
Unfolded Protein Response in Cancer: IRE1a Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability.

Amgen
39
Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity.

H. Lee Moffitt Cancer Center and Research Institute
34
Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.

Sichuan University
72
Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences
7
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Ambit Biosciences
5
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Center for Lymphoid Malignancies
1
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.

Eli Lilly
1
Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.

The Scripps Research Institute
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.

Johann Wolfgang Goethe University
33
Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model.

Genentech
46
Discovery of New Imidazo[2,1-

National Research Centre (Nrc)
4
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.

Genentech
41
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.

Beijing Normal University
22
Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory Activity.

Paraza Pharma
6
Novel Pyrido-pyrimidinones and Pteridinones as Endoribonuclease Inositol Requiring Enzyme 1 (IRE1α) Inhibitors for Treating Cancer.

Smith, Gambrell & Russell
25
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease.

University of Leicester
57
Discovery of 4

TBA
9
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.

University of Florida
2
Structural Tailoring of a Novel Fluorescent IRE-1 RNase Inhibitor to Precisely Control Its Activity.

The Wistar Institute
4
ACC inhibitor and use thereof

Nanjing Ruijie Pharma
115
DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE

University of Maryland at Baltimore
77
MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR

Kures
3
USE OF PRIDOPIDINE AND ANALOGS FOR THE TREATMENT OF ANXIETY AND DEPRESSION

Prilenia Neurotherapeutics
2243
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Cornell University
2
5-HT2A agonists for use in treatment of depression

Lophora
182
Benzimidazol-2-amines as mIDH1 inhibitors

Bayer
390
Therapeutically active compounds and their methods of use

Agios Pharmaceuticals
217
Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators

Beigene
13
Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors.

University of Pittsburgh
1
Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors.

University of Cambridge